Skip to search formSkip to main contentSkip to account menu

Orathecin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Purpose: The purpose of this phase II study was to evaluate the efficacy and tolerability of Orathecin, an oral camptothecin… 
2005
2005
4165 Background: Rubitecan (Orathecin) is a novel oral inhibitor of topoisomerase I in the camptothecin class. Methods: A Phase… 
2005
2005
The FDA has made great strides over the past twenty years in loosening drug approval regulations to speed important, life-saving… 
Review
2004
Review
2004
Rubitecan [Orathecin, 9-nitrocamptothecin, 9NC, RFS 2000] is a topoisomerase I inhibitor extracted from the bark and leaves of… 
2004
2004
2106 Background: 9NC (Orathecin) is an orally administered camptothecin analogue that has completed phase III trials for…